Abstract Details

Title Differences between Frontotemporal Dementia Patients with or without Head Injuries

Topic Aging and Dementia

Presentation(s) P07 - (-)

Poster/Presentation
Number 142

Objective

Background BACKGROUND: Frontotemporal dementia (FTD) is generally characterized by severe cognitive impairment as a result of atrophied frontal and anterior temporal regions of the brain. The main risk factor for this debilitating disorder is a history of family dementia. It has been postulated that following a traumatic brain injury (TBI), a highly inflammatory sequence of events takes place, which appears to play a significant role in the neurodegeneration observed in FTD patients.

Design/Methods DESIGN/METHODS: This retrospective study includes data from 32 patients of the Drexel Memory Disorders Clinic from January 1, 2011 until June 30, 2012. Based on physician's notes and past patient interviews, the many variables mentioned were compared. Standard statistical analyses were employed.

Results RESULTS: -65% of non-head injury patients experienced brain structure changes compared to 42% of head injury patients; -Only 25% of FTD patients with head injuries have any family history of dementia while 55% of FTD patients without head injuries have a family history; -Up to 83% of FTD patients with head injuries were found emotionally labile, angry and inappropriate, while only 20% of non-head injury patients were found emotionally labile; -Only 17% of head injury patients showed any signs of aphasia, as opposed to 75% of non-head injury patients, which showed signs of aphasia and other language problems; -Up to 66% of head injury patients showed weight issues, while only 20% of non head injury patients showed weight related issues.

Conclusions CONCLUSIONS: This study shows that there are differences in the patterns of cognitive loss and behavioral changes between head injury and no head injury FTD patients.

Authors/Disclosures
Karen Benabou PRESENTER	No disclosure on file
Carol F. Lippa, MD (Thomas Jefferson University)	Dr. Lippa has nothing to disclose.
Jan A. Hillert, MD (Karolinska Institute, Neurology R54)	Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sandoz. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Dr. Hillert has received research support from Biogen. The institution of Dr. Hillert has received research support from Celgene. The institution of Dr. Hillert has received research support from Merck. The institution of Dr. Hillert has received research support from Novartis. The institution of Dr. Hillert has received research support from Sanofi. The institution of Dr. Hillert has received research support from Roche.

��ɫ��

��ɫ��